What is the active compound in flaxseed lignan supplements?

The primary bioactive compound is secoisolariciresinol diglucoside (SDG), a polyphenol concentrated in the outer hull of flaxseed. After ingestion, gut microbiota cleave the glucoside bonds and convert SDG into the enterolignans enterodiol and enterolactone, which are the metabolically active forms that interact with estrogen receptors in human tissue.

How does flaxseed lignan differ from whole flaxseed or flaxseed oil?

Whole flaxseed contains SDG lignans, alpha-linolenic acid (ALA omega-3 fatty acid), and dietary fiber, while flaxseed oil primarily delivers ALA and contains negligible lignan content. Flaxseed lignan extract is a concentrated, isolated fraction of SDG removed from the seed coat, meaning it provides higher lignan doses per gram but lacks the fiber and omega-3 fatty acids present in whole or ground flaxseed.

Can flaxseed lignan help with menopause symptoms?

Flaxseed lignans have been theorized to reduce menopausal symptoms such as hot flashes due to their weak phytoestrogenic activity via ERα and ERβ binding. However, the current evidence base for isolated flaxseed lignan extracts specifically is insufficient, as no human RCTs focusing on the isolated lignan fraction were identified in the available research. Broader flaxseed studies show inconsistent results, and no definitive efficacy claim can be made at this time.

Is flaxseed lignan safe for people with hormone-sensitive cancers?

This remains an area of scientific uncertainty. Enterolignans act as weak SERMs and could theoretically exert either estrogenic or anti-estrogenic effects depending on the tissue, circulating estrogen levels, and receptor subtype involved. Individuals with estrogen receptor-positive breast cancer or other hormone-sensitive cancers should consult an oncologist before using flaxseed lignan supplements, as the clinical safety data in this population are not yet conclusive.

What is the typical dosage of flaxseed lignan extract in supplements?

Commercially available flaxseed lignan supplements typically provide between 50 mg and 300 mg of SDG per serving, with some research contexts using up to 600 mg SDG daily in whole flaxseed equivalent studies. Standardized lignan extracts are often labeled as a percentage of SDG content (e.g., 20–40% SDG). No established optimal clinical dose for isolated lignan extracts has been validated through controlled human trials as of the current evidence review.

What is the difference between flaxseed lignan extract and lignans found in other plant sources?

Flaxseed lignans (secoisolariciresinol diglucoside or SDG) are structurally distinct from lignans found in other sources like sesame or whole grains, with flaxseed containing significantly higher concentrations. Flaxseed lignan supplements isolate and concentrate these compounds, whereas other food sources provide them in much smaller amounts. The bioavailability and metabolic pathways of flaxseed lignans may differ from those in alternative sources due to their unique chemical structure.

Are there any known side effects or adverse reactions associated with flaxseed lignan supplements?

While flaxseed lignans are generally recognized as safe in food amounts, adverse effects at supplemental doses have not been comprehensively documented in human clinical trials. Some users report mild gastrointestinal effects such as bloating or digestive changes, particularly when introducing lignan supplements. Individuals with known lignan sensitivity or those taking certain medications should consult a healthcare provider before supplementation.

How is flaxseed lignan extract produced, and does the extraction method affect supplement quality?

Flaxseed lignan extracts are typically produced using solvent-based extraction methods to isolate and concentrate SDG from flaxseed. The extraction process can vary between manufacturers, potentially affecting the purity, concentration, and standardization of the final product. Quality supplements should provide standardization information (typically listed as % SDG content) to ensure consistency between batches and products.

Flaxseed Lignan (Linum usitatissimum)

Flaxseed lignan, derived from Linum usitatissimum, is a concentrated source of secoisolariciresinol diglucoside (SDG), a plant polyphenol that gut bacteria convert into the enterolignans enterodiol and enterolactone. These mammalian lignans weakly bind estrogen receptors and exhibit antioxidant activity, making them a subject of ongoing research in hormone-related health conditions.

Category: Other Evidence: 2/10 Tier: Emerging

Flaxseed Lignan (Linum usitatissimum) — Hermetica Encyclopedia

Origin & History

Flaxseed lignan refers to lignans primarily from the seeds of Linum usitatissimum (flax plant), originating from the Mediterranean and West Asia regions and now widely cultivated. The main lignan is secoisolariciresinol diglucoside (SDG), extracted from the seed coat using alcoholic solvents followed by purification via HPLC or GC-MS.

Historical & Cultural Context

The research dossier provides no information on historical or traditional medicine context, including systems like Ayurveda or traditional duration of use. Traditional applications cannot be described based on the available sources.

Health Benefits

• No clinical health benefits can be cited as the research dossier contains no human clinical trials, RCTs, or meta-analyses
• The provided research focuses exclusively on extraction and analytical methods
• No efficacy studies for cancer prevention, menopausal symptoms, or other health endpoints are included
• Without clinical evidence, specific health benefits cannot be substantiated
• Further clinical research is needed to establish therapeutic applications

How It Works

Secoisolariciresinol diglucoside (SDG) is hydrolyzed by intestinal bacteria into secoisolariciresinol, which is further metabolized into the enterolignans enterodiol and enterolactone. These compounds act as selective estrogen receptor modulators (SERMs), binding ERα and ERβ with weak affinity compared to endogenous estradiol, potentially modulating estrogenic and anti-estrogenic signaling depending on tissue context. SDG and its metabolites also inhibit lipid peroxidation and scavenge reactive oxygen species, partly through suppression of NF-κB-mediated inflammatory pathways.

Scientific Research

The research dossier explicitly states that search results lack specific human clinical trials, RCTs, or meta-analyses with PubMed PMIDs on flaxseed lignans. The available literature focuses on extraction and analytical methods rather than efficacy studies, with no study designs, sample sizes, or clinical outcomes detailed.

Clinical Summary

Available research on flaxseed lignan extract focuses predominantly on extraction optimization and analytical quantification methods rather than human clinical efficacy. No randomized controlled trials, prospective cohort studies, or meta-analyses were identified in the current research dossier evaluating flaxseed lignan supplementation for cancer prevention, menopausal symptom relief, cardiovascular outcomes, or glycemic control. Broader flaxseed literature (not specific to isolated lignan extracts) includes small RCTs with mixed results, but these findings cannot be directly attributed to the lignan fraction alone. The overall clinical evidence base for isolated flaxseed lignan supplements remains insufficient to support definitive efficacy claims.

Nutritional Profile

Flaxseed lignans are concentrated phytochemical extracts derived from flaxseed (Linum usitatissimum), representing one of the richest dietary sources of plant lignans. The primary bioactive compound is secoisolariciresinol diglucoside (SDG), typically concentrated at 150–300 mg per gram in standardized lignan extracts (compared to ~6–13 mg/g in whole flaxseed). SDG is a polyphenolic glycoside that serves as the precursor to the mammalian lignans enterodiol and enterolactone upon gut bacterial metabolism. Flaxseed lignan extracts are not significant sources of macronutrients in supplemental form; however, whole flaxseed context provides ~18g fat (predominantly ALA omega-3 at ~53% of fat content), ~18g protein, and ~27g fiber per 100g. The lignan fraction itself contributes negligible calories, fat, or protein. Minor phenolic compounds present include phenylpropanoid glycosides and hydroxycinnamic acid derivatives. Bioavailability of SDG is dependent on colonic microbiota conversion to enterolignans; interindividual variation is substantial (enterolactone plasma levels can vary 10–50 fold between individuals). Fat-soluble components enhance absorption when consumed with dietary fat. No significant vitamin or mineral content is attributable to the isolated lignan fraction specifically.

Preparation & Dosage

No clinically studied dosage ranges are available in the research provided, as sources emphasize analytical extraction yields rather than therapeutic dosing. Standardization methods achieve >90% SDG purity via ethanol extraction, but this pertains to manufacturing rather than clinical protocols. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Cannot be determined from available research

Safety & Interactions

Flaxseed lignans are generally considered well-tolerated at typical supplemental doses (50–600 mg SDG/day studied in broader flaxseed contexts), with gastrointestinal discomfort being the most commonly reported side effect. Due to weak estrogenic activity at estrogen receptors, flaxseed lignans should be used cautiously by individuals with hormone-sensitive conditions such as estrogen receptor-positive breast cancer, uterine fibroids, or endometriosis until more definitive clinical data exist. Potential interactions with anticoagulant medications such as warfarin and hormone therapies including oral contraceptives and HRT have been theorized based on mechanistic grounds, though direct interaction studies are limited. Pregnant and breastfeeding women should consult a healthcare provider before use due to the phytoestrogenic activity of enterolignans.